Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-125931
Filing Date
2024-11-13
Accepted
2024-11-13 07:10:23
Documents
78
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-20240930.htm   iXBRL 10-Q 2377338
2 EX-31.1 fulc-ex31_1.htm EX-31.1 12429
3 EX-31.2 fulc-ex31_2.htm EX-31.2 12420
4 EX-32.1 fulc-ex32_1.htm EX-32.1 6951
5 EX-32.2 fulc-ex32_2.htm EX-32.2 6390
  Complete submission text file 0000950170-24-125931.txt   8941310

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fulc-20240930.xsd EX-101.SCH 1253260
80 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20240930_htm.xml XML 1469068
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 241451151
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)